The Agency reviewed information submitted by the registrant to identify toxic endpoints in the following studies: acute oral, acute dermal, acute inhalation, primary eye irritation, and primary dermal irritation. The end-use product was classified in Toxicity Category IV for acute oral, dermal, and inhalation toxicity; Toxicity Category IV for primary dermal irritation; and Toxicity Category I for eye irritation. A requested waiver for dermal sensitization testing was granted based on the lack of dermal irritation and toxicity, and a lack of reported effects in users of products containing rhamnolipid biosurfactants. A requested waiver for genotoxicity was granted by the Agency based on the fact that rhamnolipid biosurfactant is not related to any known mutagen and is not a member of any chemical class or compounds containing known mutagens. Requested waivers for 90-day oral toxicity, teratogenicity, and immunotoxicity studies were granted based on the physical mode of action of the product, the demonstrated lack of oral, dermal and inhalation toxicity, and the innocuous nature of the potential breakdown products.